Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08IWD
|
|||
| Former ID |
DAP000045
|
|||
| Drug Name |
Finasteride
|
|||
| Synonyms |
Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Benign prostatic hyperplasia [ICD-11: GA90; ICD-10: N40; ICD-9: 600] | Approved | [1], [2] | |
| Therapeutic Class |
Antihyperplasia Agents
|
|||
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H36N2O2
|
|||
| Canonical SMILES |
CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C
|
|||
| InChI |
1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
|
|||
| InChIKey |
DBEPLOCGEIEOCV-WSBQPABSSA-N
|
|||
| CAS Number |
CAS 98319-26-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7847387, 7979227, 8185196, 11466745, 11467865, 11486590, 11528597, 11533303, 12014292, 12146021, 14779683, 14926633, 24724479, 24861022, 25819911, 26719811, 43115066, 46386559, 46507645, 47424400, 47646719, 48094722, 48394119, 48413780, 48416011, 49666458, 49681675, 49699149, 53790828, 56313630, 57313897, 57649138, 74382929, 75258634, 85788501, 91146246, 92125899, 92308339, 92309138, 99437022, 99444245, 103194727, 103914483, 103975037, 104312468, 117571916, 118048887, 121363570, 124658933, 124757073
|
|||
| ChEBI ID |
CHEBI:5062
|
|||
| ADReCS Drug ID | BADD_D00898 | |||
| SuperDrug ATC ID |
D11AX10; G04CB01
|
|||
| SuperDrug CAS ID |
cas=098319267
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.723; p = 0.002). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.706; p = 0.009). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.668; p = 0.002). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.564; p = 0.024). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -0.592; p = 0.031). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.54; p = 0.034). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.589; p = 0.007). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.735; p = 0.007). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.587; p = 0.004). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Odoribacter splanchnicus (log2FC = -0.496; p = 0.025). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.392; p = 0.004). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia muciniphila ATCC BAA-835
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Finasteride can be metabolized by Akkermansia muciniphila ATCC BAA-835 (log2FC = -4.039; p = 0.002). | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Acidaminococcales | ||||
|
Studied Microbe: Acidaminococcaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Acidaminococcaceae was decreased by Finasteride (p = 0.04). | |||
|
Studied Microbe: Phascolarctobacterium
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Phascolarctobacterium was decreased by Finasteride (p = 0.009). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Barnesiellaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Barnesiellaceae was decreased by Finasteride (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacteriaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Bifidobacteriaceae was decreased by Finasteride (p = 0.005). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfovibrionales | ||||
|
Studied Microbe: Desulfovibrionaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Desulfovibrionaceae was decreased by Finasteride (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Enterobacteriaceae was decreased by Finasteride (p = 0.005). | |||
|
Studied Microbe: Escherichia/Shigella sp.
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Escherichia/Shigella sp. was decreased by Finasteride (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Christensenellaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Christensenellaceae was decreased by Finasteride (p < 0.001). | |||
|
Studied Microbe: Ruminococcaceae UCG-002
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Ruminococcaceae UCG-002 was decreased by Finasteride (p < 0.0001). | |||
|
Studied Microbe: Subdoligranulum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Subdoligranulum was decreased by Finasteride (p = 0.009). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Actinobacteria
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Actinobacteria was decreased by Finasteride (p = 0.0003). | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Firmicutes was increased by Finasteride (p = 0.09). | |||
|
Studied Microbe: Proteobacteria
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Post-finasteride syndrome | |||
| Description | The abundance of Proteobacteria was decreased by Finasteride (p = 0.009). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) | Target Info | Inhibitor | [5] |
| Steroid 5-alpha-reductase 2 (SRD5A2) | Target Info | Inhibitor | [6] | |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Allopregnanolone biosynthesis | ||||
| Androgen biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Prostate cancer | ||||
| Reactome | Androgen biosynthesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6818). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Alterations of gut microbiota composition in post-finasteride patients: a pilot study. J Endocrinol Invest. 2021 Jun;44(6):1263-1273. | |||
| REF 5 | The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. | |||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.